FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2777881032> ?p ?o ?g. }

• W2777881032 abstract "Objective: To determine if there are clinical predictors of response to galcanezumab in patients with episodic migraine. Background: Migraine remains undertreated with few preventive medications available. Design/Methods: This was a post hoc analysis of a Phase II clinical trial in which patients 18–65 years of age with 4–14 migraine headache days (MHD) per month were randomized 2:1:1:1:1 to placebo or 1 of 4 galcanezumab dose groups(5, 50, 120, and 300 mg) given subcutaneously once monthly for 3 months. The objective of this post hoc analysis was to determine if there were any clinical predictors with differential treatment effects for reduction in MHD at 3months. Candidate baseline subgroup variables pre-specified before study un blinding included: number of MHD, migraine with or without aura, or triptan use, history of failure to preventive treatments, duration of migraine history, gender. To assess treatment by subgroup interaction at Month 3 for the primary efficacy measure of change from baseline in MHD, a mixed model repeated measures analysis was conducted with terms of treatment, baseline, month, subgroup, pooled investigative sites, treatment-by-month, baseline-by-month, subgroup-by-treatment, subgroup-by-month, subgroup-by-treatment-by-month interactions. Significant interaction would have a p-value Results: Compared with its respective counterpart, subgroups with statistically significantly greater treatment effect (galcanezumab vs placebo difference) at Month 3 included patients previously treated with triptans in the 300 mg dose group; duration of migraine history of >20 years in the 120 mg group; and history of failure to preventive treatments in the 300 mg dose group. Conclusions: In this posthoc analysis there is preliminary evidence that there may be some predictors of clinical response with greater treatment effects in episodic migraineurs. These include prior triptan use, migraine history >20 years, and history of failure to preventive treatments. Study Supported by: Eli Lilly and Company, Indianapolis, IN Disclosure: Dr. Aurora has received personal compensation for activities with Eli Lilly and Company as an employee and Allergan as a consultant. Dr. Aurora hold stock and/or stock options in Lilly and Company. Dr. Oakes has received personal compensation for activities with Eli Lilly and Company as an employee. Dr. Zhang has received personal compensation for activities with Eli Lilly and Company as an employee. J. Ahl has received personal compensation for activities with Eli Lilly and Company as an employee. Dr. Martinez has received personal compensation for activities with Eli Lilly and Company as an employee. Dr. Martinez holds stock and/or stock options in Eli Lilly and Company." @default.
• W2777881032 created "2018-01-05" @default.
• W2777881032 creator A5026984704 @default.
• W2777881032 creator A5027240972 @default.
• W2777881032 creator A5029091280 @default.
• W2777881032 creator A5050512906 @default.
• W2777881032 creator A5059017023 @default.
• W2777881032 date "2017-04-18" @default.
• W2777881032 modified "2023-09-24" @default.
• W2777881032 title "Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab (P2.177)" @default.
• W2777881032 hasPublicationYear "2017" @default.
• W2777881032 type Work @default.
• W2777881032 sameAs 2777881032 @default.
• W2777881032 citedByCount "0" @default.
• W2777881032 crossrefType "journal-article" @default.
• W2777881032 hasAuthorship W2777881032A5026984704 @default.
• W2777881032 hasAuthorship W2777881032A5027240972 @default.
• W2777881032 hasAuthorship W2777881032A5029091280 @default.
• W2777881032 hasAuthorship W2777881032A5050512906 @default.
• W2777881032 hasAuthorship W2777881032A5059017023 @default.
• W2777881032 hasConcept C102959455 @default.
• W2777881032 hasConcept C105795698 @default.
• W2777881032 hasConcept C126322002 @default.
• W2777881032 hasConcept C142724271 @default.
• W2777881032 hasConcept C168563851 @default.
• W2777881032 hasConcept C1862650 @default.
• W2777881032 hasConcept C187960798 @default.
• W2777881032 hasConcept C204787440 @default.
• W2777881032 hasConcept C27081682 @default.
• W2777881032 hasConcept C2777119127 @default.
• W2777881032 hasConcept C2778541695 @default.
• W2777881032 hasConcept C2910587157 @default.
• W2777881032 hasConcept C33923547 @default.
• W2777881032 hasConcept C535046627 @default.
• W2777881032 hasConcept C67761136 @default.
• W2777881032 hasConcept C71924100 @default.
• W2777881032 hasConcept C95190672 @default.
• W2777881032 hasConceptScore W2777881032C102959455 @default.
• W2777881032 hasConceptScore W2777881032C105795698 @default.
• W2777881032 hasConceptScore W2777881032C126322002 @default.
• W2777881032 hasConceptScore W2777881032C142724271 @default.
• W2777881032 hasConceptScore W2777881032C168563851 @default.
• W2777881032 hasConceptScore W2777881032C1862650 @default.
• W2777881032 hasConceptScore W2777881032C187960798 @default.
• W2777881032 hasConceptScore W2777881032C204787440 @default.
• W2777881032 hasConceptScore W2777881032C27081682 @default.
• W2777881032 hasConceptScore W2777881032C2777119127 @default.
• W2777881032 hasConceptScore W2777881032C2778541695 @default.
• W2777881032 hasConceptScore W2777881032C2910587157 @default.
• W2777881032 hasConceptScore W2777881032C33923547 @default.
• W2777881032 hasConceptScore W2777881032C535046627 @default.
• W2777881032 hasConceptScore W2777881032C67761136 @default.
• W2777881032 hasConceptScore W2777881032C71924100 @default.
• W2777881032 hasConceptScore W2777881032C95190672 @default.
• W2777881032 hasLocation W27778810321 @default.
• W2777881032 hasOpenAccess W2777881032 @default.
• W2777881032 hasPrimaryLocation W27778810321 @default.
• W2777881032 hasRelatedWork W1481588157 @default.
• W2777881032 hasRelatedWork W14941675 @default.
• W2777881032 hasRelatedWork W1555860353 @default.
• W2777881032 hasRelatedWork W1657838061 @default.
• W2777881032 hasRelatedWork W2335934270 @default.
• W2777881032 hasRelatedWork W2341533085 @default.
• W2777881032 hasRelatedWork W2794514658 @default.
• W2777881032 hasRelatedWork W2795807623 @default.
• W2777881032 hasRelatedWork W2805066472 @default.
• W2777881032 hasRelatedWork W2808055426 @default.
• W2777881032 hasRelatedWork W2808567508 @default.
• W2777881032 hasRelatedWork W2809684180 @default.
• W2777881032 hasRelatedWork W2888596619 @default.
• W2777881032 hasRelatedWork W2899506043 @default.
• W2777881032 hasRelatedWork W3014490536 @default.
• W2777881032 hasRelatedWork W3084499749 @default.
• W2777881032 hasRelatedWork W3126954968 @default.
• W2777881032 hasRelatedWork W3132024420 @default.
• W2777881032 hasRelatedWork W3159959646 @default.
• W2777881032 hasRelatedWork W3197018837 @default.
• W2777881032 hasVolume "88" @default.
• W2777881032 isParatext "false" @default.
• W2777881032 isRetracted "false" @default.
• W2777881032 magId "2777881032" @default.
• W2777881032 workType "article" @default.